Innovation In The Biopharmaceutical Industry

Author : Rifat A. Atun,Desmond John Sheridan
Publisher : World Scientific
Page : 153 pages
File Size : 41,5 Mb
Release : 2007
Category : Medical
ISBN : 9789812770974

Get Book

Innovation in the Biopharmaceutical Industry by Rifat A. Atun,Desmond John Sheridan Pdf

Innovation is at the heart of all advances and has the capacity to solve problems facing humanity. Societies which have turned away from innovation and technological development have failed in their ability to support their populations. Understanding the nature of innovation in the life sciences and in particular healthcare, how it operates, what enables and hinders it is therefore of great importance to meeting the challenges ahead. This book, originally and concurrently published in the International Journal of Innovation Management, Vol. 11, No. 2, 2007, offers the latest research and insights concerning innovation in the biopharmaceutical industry.

Author : Anonim
Publisher : Unknown
Page : 128 pages
File Size : 40,5 Mb
Release : 2024-06-30
Category : Electronic
ISBN : 9789814475433

Get Book

Innovation in the Biopharmaceutical Industry by Anonim Pdf

Author : Bruce Rasmussen
Publisher : Edward Elgar Publishing
Page : 335 pages
File Size : 43,7 Mb
Release : 2010-01-01
Category : Business & Economics
ISBN : 9781849805513

Get Book

Innovation and Commercialisation in the Biopharmaceutical Industry by Bruce Rasmussen Pdf

The processes of discovery, testing and distribution of new medicines have undergone radical change in recent decades, from a focus on small molecule drugs to biomedicine and related technologies. Bruce Rasmussen very effectively draws upon modern theories of the firm, data analysis, and case studies to provide important insights into the consequences of this change. He offers convincing evidence that contradicts the widely-held view that the biopharmaceutical sector has not generated considerable economic value. Frank R. Lichtenberg, Columbia University, US Bio- and pharmaceutical industry discovery is a distressed asset today. Why? Bruce Rasmussen s book is a timely and very informative work, building on rich data sources and extensive economic research, on a subject of concern to us all. Is medicine discovery in permanent decline? Are the biotechnology and traditional pharma groups on a collision course, will the traditional group absorb the new, will integration take place, will a new discovery model emerge? I commend Bruce s book to all who wish to understand what is happening. David W. Anstice, Merck & Co., Inc. This path-breaking book addresses the ongoing implications for traditional pharmaceutical companies and biopharmaceutical start-ups of the realignment of the industry knowledge-base. The theoretical approach draws on the modern theory of the firm and related ideas in order to better define the concept of the business model, which is employed to guide the case studies and empirical analysis in the book. The author shows that while traditional pharmaceutical companies have successfully adjusted their business models to meet the challenges of biotechnology, biopharmaceutical start-ups have experienced more problems. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. However, this has been captured disproportionately by a handful of large, fully-integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical companies. This highly focused book will be a captivating read for innovation and biopharmaceutical industry analysts, as well as advisers formulating policies to support the development of the biopharmaceutical sector. Academics working on innovation and biotechnology, as well as scientists engaged in research in the life sciences, will also find this book of particular interest.

Author : Ruchin Kansal,Jeff Huth
Publisher : Taylor & Francis
Page : 190 pages
File Size : 40,5 Mb
Release : 2018-05-11
Category : Medical
ISBN : 9780429015922

Get Book

Redefining Innovation by Ruchin Kansal,Jeff Huth Pdf

Most people marvel at the level of innovation demonstrated by the biopharmaceutical industry in bringing new products to the market – especially in the past 20 years. However, there is a crisis looming in the industry that should be a concern to all of us who take for granted the constant pace at which new treatments, and increasingly cures, have emerged from the laboratories of current sector incumbents. In the book, we examine the evolution of the biopharmaceutical industry to understand how it became what we term a "unicorn industry" with a unique, US-centered business model that has led to multiple blockbuster products (aka, unicorns) year after year. We explore how past success has created perceived barriers to innovation diversification beyond the chemical or biological-based biopharmaceutical product, and highlight the warning signs of the industry’s decline. We define a potential pathway for transforming the industry’s business model by broadening the definition, sources, and enablers of innovation beyond the traditional biopharmaceutical product. We introduce and advocate for the 80-80 Rule - "Being 80% confident that you will only be 80% right the first time should feel normal." The 80-80 Rule is a theme that emphasizes speed and willingness to embrace uncertainty and overcome internal barriers to change. It sets the standard for redefining innovation as a platform to reignite growth of the biopharmaceutical industry.

Author : Alexander Schuhmacher,Markus Hinder,Oliver Gassmann
Publisher : John Wiley & Sons
Page : 508 pages
File Size : 51,6 Mb
Release : 2016-01-19
Category : Science
ISBN : 9783527693436

Get Book

Value Creation in the Pharmaceutical Industry by Alexander Schuhmacher,Markus Hinder,Oliver Gassmann Pdf

This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.

Author : Oliver Gassmann,Alexander Schuhmacher,Max von Zedtwitz,Gerrit Reepmeyer
Publisher : Springer
Page : 179 pages
File Size : 44,8 Mb
Release : 2018-05-10
Category : Business & Economics
ISBN : 9783319668338

Get Book

Leading Pharmaceutical Innovation by Oliver Gassmann,Alexander Schuhmacher,Max von Zedtwitz,Gerrit Reepmeyer Pdf

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Author : OECD
Publisher : OECD Publishing
Page : 187 pages
File Size : 42,9 Mb
Release : 2006-03-29
Category : Electronic
ISBN : 9789264014046

Get Book

Innovation in Pharmaceutical Biotechnology Comparing National Innovation Systems at the Sectoral Level by OECD Pdf

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries - Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain - and makes recommendations advocating an integrated policy approach.

Author : World Intellectual Property Organization,Michael S. Kinch,Julio Raffo
Publisher : WIPO
Page : 14 pages
File Size : 45,8 Mb
Release : 2015
Category : Law
ISBN : 8210379456XXX

Get Book

Sources of Biopharmaceutical Innovation: An Assessment of Intellectual Property by World Intellectual Property Organization,Michael S. Kinch,Julio Raffo Pdf

An analysis of new, FDA-approved molecular entities reveals dynamism in terms of new innovation. An assessment of the first patent for each drug reveals that the pharmaceutical industry, particularly large, established companies in North America, tend to dominate the field. Whereas inventors continue to found biotechnology companies at a steady rate, recent trends suggest these inventors more often come from the private sector.

Author : Michael S. Kinch,Julio D. Raffo
Publisher : Unknown
Page : 0 pages
File Size : 53,9 Mb
Release : 2023
Category : Electronic
ISBN : OCLC:1398456362

Get Book

Sources of Biopharmaceutical Innovation by Michael S. Kinch,Julio D. Raffo Pdf

An analysis of new, FDA-approved molecular entities reveals dynamism in terms of new innovation. An assessment of the first patent for each drug reveals that the pharmaceutical industry, particularly large, established companies in North America, tend to dominate the field. Whereas inventors continue to found biotechnology companies at a steady rate, recent trends suggest these inventors more often come from the private sector.

Author : Min Ding,Jehoshua Eliashberg,Stefan Stremersch
Publisher : Springer Science & Business Media
Page : 763 pages
File Size : 54,5 Mb
Release : 2013-10-31
Category : Medical
ISBN : 9781461478010

Get Book

Innovation and Marketing in the Pharmaceutical Industry by Min Ding,Jehoshua Eliashberg,Stefan Stremersch Pdf

The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike.

Author : Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz
Publisher : Springer Science & Business Media
Page : 194 pages
File Size : 54,9 Mb
Release : 2008-02-19
Category : Business & Economics
ISBN : 9783540776369

Get Book

Leading Pharmaceutical Innovation by Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz Pdf

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Author : Organisation for Economic Co-operation and Development
Publisher : OECD
Page : 196 pages
File Size : 46,7 Mb
Release : 2006-04-11
Category : Medical
ISBN : UCSD:31822035655588

Get Book

Innovation in Pharmaceutical Biotechnology by Organisation for Economic Co-operation and Development Pdf

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries - Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain - and makes recommendations advocating an integrated policy approach.

Author : Alexander Schuhmacher,Markus Hinder,Oliver Gassmann
Publisher : Unknown
Page : 128 pages
File Size : 46,8 Mb
Release : 2016
Category : Pharmaceutical industry
ISBN : 3527693408

Get Book

Value Creation in the Pharmaceutical Industry by Alexander Schuhmacher,Markus Hinder,Oliver Gassmann Pdf

Author : Patricia M. Danzon,Sean Nicholson
Publisher : Oxford University Press
Page : 624 pages
File Size : 46,8 Mb
Release : 2012-04-12
Category : Business & Economics
ISBN : 9780199909261

Get Book

The Oxford Handbook of the Economics of the Biopharmaceutical Industry by Patricia M. Danzon,Sean Nicholson Pdf

The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry.

Author : Irina Haracoglou
Publisher : Edward Elgar Publishing
Page : 272 pages
File Size : 44,5 Mb
Release : 2008-01-01
Category : Law
ISBN : 9781848440111

Get Book

Competition Law and Patents by Irina Haracoglou Pdf

This is an incredibly interesting book on an increasingly pertinent topic. . . the book is succinctly written and provides a comprehensive overview of EU law. . . providing a really useful analysis of the European cases concerned with the imposition of a duty to deal in relation to intellectual property. . . This book is a thoroughly enjoyable read, and perhaps because of its brevity the author retains her focus on the central issues being examined. I found it to be engaging and thought provoking. Jane Nielsen, Competition and Consumer Law Journal The book caters for various groups ranging from those with a general interest in competition law, patent law and/or biopharmaceuticals, to students who want to understand how competition and intellectual property work in practice (or to understand the interface between the two policies), and from practitioners and policymakers to people within the biopharmaceutical industry itself. Journal of Intellectual Property Rights Using the example of research tools in biopharmaceutical research and innovation, this book examines the complexities of the relationship between two fundamental areas of law and policy intellectual property rights and competition law. It addresses a question that is certain to become paramount in other industries also: how to strike the balance between initial and follow-on innovation so as to ensure that access to essential research tools (or other fundamental elements to follow-on innovation) is not impeded. The book concludes by suggesting how competition law could be used to complement the patent balance. Competition Law and Patents caters for various groups ranging from those with a general interest in competition law, patent law and/or biopharmaceuticals, to students who want to understand how competition and intellectual property work in practice (or to understand the interface between the two policies), and from practitioners and policymakers to people within the biopharmaceutical industry itself.